Format

Send to

Choose Destination
Cancer Immun. 2010 Jan 7;10:1.

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

Author information

1
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, New York, NY 10065, USA.

Erratum in

  • Cancer Immun. 2010 Feb 24;10:5. Ritter, Erika [added].

Abstract

Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters.

PMID:
20052966
PMCID:
PMC2964016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Academy of Cancer Immunology Icon for PubMed Central
Loading ...
Support Center